PRECIGEN, INC. Business Acquisition, Pro Forma Revenue
PRECIGEN, INC. (PGEN) reported Business Acquisition, Pro Forma Revenue of $154.19 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2018-11-08
- PRECIGEN, INC. business acquisition, pro forma revenue for the quarter ending 2017-09-30 was $46.02M, a 6.39% decline year-over-year.
- PRECIGEN, INC. business acquisition, pro forma revenue for the quarter ending 2017-06-30 was $54.55M, a 3.85% increase year-over-year.
- PRECIGEN, INC. business acquisition, pro forma revenue for the quarter ending 2017-03-31 was $53.86M.
- PRECIGEN, INC. business acquisition, pro forma revenue for the quarter ending 2016-09-30 was $49.16M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month |
|---|---|---|---|
| 2017-09-30 | $46.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $100.57M derived: sum of 2 quarters · filed 2018-11-08 | $154.19M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $54.55M 10-Q · filed 2018-08-13 | $108.17M 10-Q · filed 2018-08-13 | |
| 2017-03-31 | $53.86M 10-Q/A · filed 2018-08-13 | ||
| 2016-09-30 | $49.16M 10-Q · filed 2017-11-09 | $101.69M derived: sum of 2 quarters · filed 2017-11-09 | $145.41M 10-Q · filed 2017-11-09 |
| 2016-06-30 | $52.53M 10-Q · filed 2017-08-09 | $96.25M 10-Q · filed 2017-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |